Incidence and risk factors of herpes zoster in human immunodeficiency virus-positive patients initiating combination antiretroviral therapy in Taiwan  by Lee, Yi-Chieh et al.
+ MODEL
Journal of Microbiology, Immunology and Infection (2016) xx, 1e7Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comORIGINAL ARTICLEIncidence and risk factors of herpes zoster in
human immunodeficiency virus-positive
patients initiating combination
antiretroviral therapy in Taiwan
Yi-Chieh Lee a, Chien-Ching Hung b, Mao-Song Tsai c,
Jun-Yu Zhang d, Pei-Ying Wu d, Shang-Ping Yang d,
Yu-Zhen Luo d, Hsi-Yen Chang d, Wen-Chun Liu b,
Hsin-Yun Sun b,*, Shan-Chwen Chang ba Department of Internal Medicine, Lotung Poh-Ai Hospital, Lo-Hsu Medical Foundation, I-Lan, Taiwan
b Department of Internal Medicine, National Taiwan University Hospital and National Taiwan
University College of Medicine, Taipei, Taiwan
c Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
d Center of Infection Control, National Taiwan University Hospital, Taipei, TaiwanReceived 28 January 2016; received in revised form 17 March 2016; accepted 1 April 2016
Available online - - -KEYWORDS
AIDS;
dermatologic
complications;
immunosuppression;
varicella-zoster* Corresponding author. Department
E-mail address: hysun@ntu.edu.tw
Please cite this article in press as: Le
patients initiating combination anti
dx.doi.org/10.1016/j.jmii.2016.04.01
http://dx.doi.org/10.1016/j.jmii.2016
1684-1182/Copyright ª 2016, Taiwan S
BY-NC-ND license (http://creativecomAbstract Background/Purpose: To obtain current epidemiological data for better vaccina-
tion policies, this study aimed to assess the incidence and risk factors of herpes zoster in hu-
man immunodeficiency virus (HIV)-positive patients initiating combination antiretroviral
therapy (cART) in Taiwan.
Methods: Between June, 2012 and May, 2015, we prospectively identified zoster cases in HIV-
positive patients initiating cART. Clinical information was collected on demographics, prior
zoster, plasma HIV-1 RNA load (PVL), and CD4 count at baseline and during follow up. A
caseecontrol study by 1:2 matched pairs was used to identify the risk factors for zoster devel-
opment.
Results: During the 3-year study period, 826 patients with a mean age of 32.9 years were
included, and 7.7% had prior zoster. The mean baseline CD4 count and PVL were 286 cells/
mL and 4.90 log10 copies/mL, respectively. Fifty-four (6.5%) patients developed zoster after
initiation of cART, with 43 episodes (79.6%) occurring within 1 year of cART initiation, whichof Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan.
(H.-Y. Sun).
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dx.doi.org/10.1016/j.jmii.2016.04.01corresponded to an overall incidence rate of 3.61/100 person-years. The multivariate analysis
revealed that prior zoster (adjusted odds ratioZ 3.143; 95% confidence interval, 1.385e7.133)
and baseline CD4 count < 200 cells/mL (adjusted odds ratioZ 2.034; 95% confidence interval,
1.020e4.057) were independent risk factors for zoster in HIV-positive patients initiating cART.
In caseecontrol study, prior zoster and baseline PVL > 5 log10 copies/mL were risk factors for
zoster development after cART initiation in multivariate analysis.
Conclusions: Herpes zoster occurred in 6.5% of HIV-positive Taiwanese patients after initiation
of cART, which was associated with prior zoster and baseline CD4 count < 200 cells/mL or base-
line PVL > 5 log10 copies/mL.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Herpes zoster, also called shingles, is most often seen in the
elderly population. It also commonly occurs in human im-
munodeficiency virus (HIV)-positive patients.1e3 Prior to
the introduction of combination antiretroviral therapy
(cART), the incidence of herpes zoster was estimated to be
10e30 times greater in HIV-positive patients than in HIV-
negative individuals.1,4,5 Several studies reported inci-
dence rates of 2.5e3.2 cases/100 person-years in different
HIV-positive cohorts.3,6 A low CD4 count was the risk factor
for developement of herpes zoster.4,7 After the introduc-
tion of cART, the incidence of herpes zoster declined sig-
nificantly7e10; 1.2 cases/100 person-years was observed in
Germany and 0.9 cases/100 person-years in the United
States in the cART era.9,10 This decrease was mainly
attributable to the restoration of immunity with cART.
However, the incidence remains higher in HIV-positive pa-
tients in the cART era than that in the general population of
resource-rich countries, which ranges from 0.2/100 person-
years to 0.5/100 person-years.11,12 Complication rates are
also higher in HIV-positive patients than in the age-matched
general population (27e28% vs. 10e13%).6,10,13,14 There-
fore, use of herpes zoster vaccine may be considered in
HIV-positive patients to prevent herpes zoster and its
related complications.
Live attenuated herpes zoster vaccine (LAHZV) was
recommended to HIV-positive adults with a CD4 count
>200 cells/mL.15,16 Recently, an adjuvanted herpes zoster
subunit vaccine, called HZ/su vaccine, demonstrated sig-
nificant risk reduction of herpes zoster in adults
aged  50 years.17 Given the concerns about the theoret-
ical risk that the attenuated live vaccines may cause serious
disease in immunocompromised hosts, this HZ/su vaccine
has the potential to benefit HIV-positive patients.18
In Taiwan, Hung et al7 reported that the incidence of
herpes zoster in HIV-positive patients had declined from
17.21/100 person-years in the pre-cART era (prior to 1997)
to 5.05/100 person-years in the post-cART era (between
1997 and 2003) (p < 0.0001), and baseline CD4 count was a
significant risk factor associated with herpes zoster. To
obtain current epidemiological data for better vaccination
policies, this study aimed to assess the incidence and
identify risk factors of herpes zoster in HIV-positive patients
initiating cART in Taiwan.e Y-C, et al., Incidence and risk f
retroviral therapy in Taiwan, Jou
1Materials and methods
Patients and setting
Between June 1, 2012 and May 31, 2015, we conducted a
prospective cohort study to identify cases of herpes zoster
in cART-naı¨ve HIV-positive adult patients who initiated
cART at the National Taiwan University Hospital, Taipei,
Taiwan. Patients were followed from the initiation of cART
until the date of first episode of herpes zoster, loss to
follow up, death, or end of observation (December 31,
2015). Herpes zoster was diagnosed based on the charac-
teristic skin findings, whereas previous herpes zoster was
defined as having an episode of herpes zoster prior to the
initiation of cART.
In Taiwan, cART has been provided free of charge since
its introduction in April 1997, and HIV-positive Taiwanese
patients receive HIV care according to the national treat-
ment guidelines at designated hospitals around Taiwan.
Plasma HIV-1 RNA load (PVL) and CD4 count were deter-
mined at baseline, 4 weeks after initiation of cART, and
every 12 weeks thereafter within the 1st year of cART and
every 24 weeks subsequently in patients who are on stable
cART with good viral suppression. All of the patients were
enrolled in the case management program implemented by
the Taiwan Centers for Disease Control to provide support,
counseling, and linkage to and retention in HIV care fort the
HIV-positive patients.
During the study period, cART was defined as combi-
nations of two nucleos(t)ide reverse-transcriptase in-
hibitors with one non-nucleoside reverse-transcriptase
inhibitor, boosted protease inhibitor or unboosted ata-
zanavir, or integrase inhibitor. PVL and CD4 count quan-
tified with the use of the Cobas Amplicor HIV-1 Monitor
Test, version 1.5, (Roche Diagnostics Corporation, Indi-
anapolis, IN, USA) and FACSFlow (Becton Dickinson, CA),
respectively.Study design and data collection
We used a standardized case record form to collect in-
formation on the demographic and clinical characteristics
of the patients, including age, sex, risk behaviors of HIV-1
transmission, prior episode of herpes zoster, duration fromactors of herpes zoster in human immunodeficiency virus-positive
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well as PVL and CD4 count at baseline and during follow
up. To better delineate the risk factor for development of
herpes zoster, a caseecontrol study was conducted with
two control patients without herpes zoster who were
matched for one case patient with herpes zoster with re-
gard to age (3 years), sex, risk behaviors, and date of
cART initiation (2 weeks). Only the first episode of herpes
zoster was included for analysis. The patients were
censored when herpes zoster occurred after initiation of
cART, when the patients were lost to follow up, or when
the observation ended (December 31, 2015), whichever
occurred first.
The study was approved by the Research Ethics Com-
mittee of the hospital (Registration Number, 201003112R),
and the requirement for written informed consent from
participants prior to participation in the study was waived.Table 1 Clinical characteristics of HIV-positive patients with
antiretrovial therapy between June 1, 2012 and May 30, 2015.
Variable All patients Pa
Patient no. 826 (100) 54
Age (y) 32.9  9.3 36
Male sex 801 (97) 53
Risk of HIV infection
Homosexuals 769 (93.1) 52
Heterosexuals 41 (5.0) 2 (
IDU 15 (1.8) 0 (
Others 1 (0.1) 0 (
Prior herpes zoster 56 (7.7) 9 (
AZT use 358 (43.3) 25
Switch from AZT to other agents 248 (30.0) 18
Duration from ART initiation to
the development of zoster (d)
227  265 22
<1 mo of ART use NA 8 (
1e3 mo of ART use NA 13
3e6 mo of ART use NA 11
6e12 mo of ART use NA 11
>12 mo of ART use NA 11
Baseline CD4 (cells/mL) 286  187 20
500 cells/mL 86 (10.5) 3 (
350e499 cells/mL 199 (24.2) 8 (
200e349 cells/mL 271 (33.0) 15
<200 cells/mL 266 (32.4) 28
CD4 1 mo post-ART (cells/mL) 401  212 34
<200 cells/mL 139 (17.9) 13
CD4 4 mo post-ART (cells/mL) 453  224 40
<200 cells/mL 101 (14.0) 11
Baseline PVL (log10 copies/mL) 4.90  0.73 5.2
>5 log10 copies/mL 340 (41.3) 33
PVL 1 mo post-ART log10 copies/mL
(log10 copies/mL)
2.60  0.82 2.9
>2 log10 copies/mL 617 (78.5) 45
<200 copies/mL 288 (36.6) 11
PVL 4 mo post-ART (log10 copies/mL) 2.60  0.82 2.1
>2 log10 copies/mL 165 (22.9) 21
<200 copies/mL 616 (85.4) 39
Data are presented as mean  SD or n (%).
ARTZ antiretroviral therapy; AZTZ zidovudine; HIVZ human immu
PVL Z plasma HIV-1 RNA load; SD Z standard deviation.
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Statistical analyses were performed using SPSS software
version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous vari-
ables were reported as mean  standard deviation (SD), and
compared using Student t test. Categorical variables were
expressed as percentage of the total number of patients
analyzed, and compared using chi-square test. To identify the
factors associated with development of herpes zoster, the
variables with p values < 0.05 in univariate analysis were
entered into themultivariate logistic regression analysis. The
KaplaneMeier method was used to assess time to cumulative
probabilities of herpes zoster free condition by different
categories of baseline CD4 count (<200 cells/mL,
200e349 cells/mL, 350e499 cells/mL, and 500 cells/mL,
respectively), which were compared using log-rank test. A p
value < 0.05 was considered statistically significant.and without herpes zoster after initiation of combination
tients with zoster Patients without zoster p
(6.5) 772 (93.5)
.3  10.1 32.7  9.2 0.005
(98.1) 748 (96.9) 0.912
(96.3) 717 (92.9) 0.326
3.7) 39 (5.1)
0) 15 (1.9)
0) 1 (0.1)
18.8) 47 (6.9) 0.007
(46.3) 333 (43.1) 0.650
(33.3) 230 (29.8) 0.583
7  265 NA NA
14.8) NA NA
(24.1) NA NA
(20.4) NA NA
(20.4) NA NA
(20.4) NA NA
8  156 292  187 0.001
5.6) 83 (10.8) 0.013
14.8) 191 (24.9)
(27.8) 256 (33.3)
(51.9) 238 (31.0) 0.002
4  179 405  214 0.043
(24.5) 126 (17.4) 0.193
3  213 457  225 0.091
(20.8) 90 (13.5) 0.142
2  0.72 4.87  0.72 0.001
(61.1) 307 (39.9) 0.002
3  0.84 2.58  0.81 0.002
(84.9) 572 (78.0) 0.240
(20.8) 277 (37.8) 0.013
6  1.09 1.74  0.79 0.008
(40.4) 144 (21.5) 0.002
(73.6) 577 (86.4) 0.011
nodeficiency virus; IDUZ injected drug user; NAZ not available;
actors of herpes zoster in human immunodeficiency virus-positive
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Figure 1. KaplaneMeier plots showing the cumulative
probability of herpes zoster-free condition in human immuno-
deficiency virus (HIV)-positive patients initiating combination
antiretroviral therapy with different categories of baseline CD4
counts.
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During the 3-year study period, a total of 826 patients
initiated cART at National Taiwan University Hospital. The
patients had a mean age of 32.9 years; 97.0% were men;
93.1% were men who have sex with men; and 7.7% had prior
herpes zoster. The mean baseline CD4 count and PVL were
286 cells/mL and 4.90 log10 copies/mL, respectively. Almost
one-third of the patients (32.4%) had a baseline CD4
count < 200 cells/mL (Table 1). cART containing zidovudine/
lamivudine was initiated in 43.3% (358/826) of the patients;
however, 69.3% of those 358 patients initiating zidovudine-
containing regimens had to switch from zidovudine/lam-
ivudine to other nucleoside reverse transcriptase inhibitors.
After a mean observation duration of 634 days (SD, 348),
herpes zoster developed in 54 patients (6.5%) after cART
initiation, and nine (18.8%) of them had had herpes zoster
prior to cART initiation. This corresponded to an overall
incidence rate of 3.61/100 person-years. The mean interval
from cART initiation to onset of herpes zoster was 227 days
(SD, 265). Most of the episodes (79.6%) occurred within
1 year of cART initiation.
Demographic data and clinical characteristics between
patients with and without development of herpes zoster
after initiation of cART are shown in Table 1. Compared
with patients without herpes zoster after cART, those with
herpes zoster were older (mean age, 36.3 years vs.Table 2 Multivariate analysis for risk factors associated with the
of combination antiretroviral therapy.
Variable Reference
Prior zoster No prior zoster
Age Continuous variables
Baseline CD4 count <200 cells/mL Baseline CD4 < 200 ce
Baseline PVL > 5 log10 copies/mL Baseline PVL < 5 log c
CI Z confidence interval; HIV Z human immunodeficiency virus; OR
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dx.doi.org/10.1016/j.jmii.2016.04.01132.7 years, p Z 0.005) and more likely to have had prior
herpes zoster (18.8% vs. 6.9%, pZ 0.007), and had a lower
mean baseline CD4 count (208 cells/mL vs. 292 cells/mL,
p Z 0.001) and a higher mean baseline PVL (5.22
log10 copies/mL vs. 4.87 log10 copies/mL, p Z 0.001).
One month after initiation of cART, patients with herpes
zoster continued to have a lower mean CD4 count
(344 cells/mL vs. 405 cells/mL, p Z 0.043) and a higher
mean PVL (2.93 log10 copies/mL vs. 2.58 log10 copies/mL,
p Z 0.002). Four months after initiation of cART, patients
with herpes zoster tended to have a lower mean CD4 count
(403 cells/mL vs. 457 cells/mL, p Z 0.091) but had a higher
mean PVL (2.15 log10 copies/mL vs. 1.74 log10 copies/mL,
p Z 0.010).
KaplaneMeier plots for cumulative probability of herpes
zoster in patients with different categories of baseline CD4
counts during observation are shown in Figure 1. Patients
with lower baseline CD4 counts were more likely to develop
zoster (log-rank test p Z 0.012; Figure 1). In multivariate
analysis, prior herpes zoster [adjusted odds ratio
(AOR) Z 3.143; 95% confidence interval (CI), 1.385e7.133;
p Z 0.006] and baseline CD4 count < 200 cells/mL (AOR
2.034, 95% CI 1.020e4.057, p Z 0.044) were independent
risk factors for herpes zoster in HIV-positive patients initi-
ating cART (Table 2).
In the caseecontrol study, the clinical characteristics of
the matched pairs (1:2) of patients with and without
development of herpes zoster after initiation of cART are
shown in Table 3. Six case patients did not have suitable
controls, and only one matched control was identified for
each of 10 patients. Compared with control patients, case
patients were more likely to have prior herpes zoster (18.8%
vs. 3.8%, p Z 0.012), and had a lower mean baseline CD4
count (208 cells/mL vs. 284 cells/mL, p Z 0.015) and a
higher mean baseline PVL (5.22 log10 copies/mL vs. 4.80
log10 copies/mL, p < 0.001). One month and 4 months after
initiation of cART, case patients had a higher mean PVL
[2.93 log10 copies/mL vs. 2.51 log10 copies/mL (p Z 0.004)
and 2.15 log10 copies/mL vs. 1.71 log10 copies/mL
(p Z 0.014), respectively]. Associated factors with devel-
opment of herpes zoster in multivariate analysis included
prior herpes zoster (AOR Z 4.735; 95% CI, 1.122e19.990;
p Z 0.034) and baseline PVL > 5 log10 copies/mL
(AOR Z 2.963; 95% CI, 1.001e8.774; p Z 0.050) (Table 4).Discussion
In this cohort of ART-naive HIV-positive patients, 6.5%
experienced herpes zoster after cART initiation. Other
studies of similar populations (homosexual males ageddevelopment of zoster in HIV-positive patients after initiation
OR 95% CI p
3.143 1.385e7.133 0.006
1.016 0.985e1.047 0.317
lls/mL 2.034 1.020e4.057 0.044
opies/mL 1.542 0.789e3.013 0.205
Z odds ratio; PVL Z plasma HIV-1 RNA load.
actors of herpes zoster in human immunodeficiency virus-positive
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Table 3 Clinical characteristics in matched pairs (1:2) of
HIV-positive patients with and without herpes zoster after
initiation of combination antiretroviral therapy.
Variable Patients
with zoster
Patients
without zoster
p
No. of patients 54 (38.6) 86 (61.4)
Age (y) 36.3  10.1 34.3  7.8 0.191
Male 53 (98.1) 86 (100) 0.386
Risk of HIV infection
Homosexuals 52 (96.3) 85 (98.8) 0.681
Heterosexuals 2 (3.7) 1 (1.2)
IDU 0 (0) 0 (0)
Others 0 (0) 0 (0)
Prior zoster 9 (18.8) 3 (3.8) 0.012
Baseline CD4
(cells/mL)
208  156 284  192 0.015
500 cells/mL 3 (5.6) 19 (13.8) 0.022
350e500 cells/mL 8 (14.8) 30 (21.7)
200e349 cells/mL 15 (27.8) 49 (35.5)
<200 cells/mL 28 (51.9) 28 (32.6) 0.023
AZT use 25 (46.3) 29 (33.7) 0.137
Switch from AZT to
other agents
18 (33.3) 25 (29.1) 0.595
CD4 1 mo post-ART
(cells/mL)
344  179 374  201 0.368
<200 cells/mL 13 (24.5) 15 (18.5) 0.403
CD4 4 mo post-ART
(cells/uL)
403  213 417  210 0.705
<200 cells/mL 11 (20.8) 15 (18.5) 0.749
Baseline PVL
(log10 copies/mL)
5.22  0.72 4.80  0.59 <0.001
>5 log10 copies/mL 33 (61.1) 28 (32.6) 0.001
PVL 1 mo post-ART
(log10 copies/mL)
2.93  0.84 2.51  0.81 0.004
>2 log10 copies/mL 45 (84.9) 64 (78.0) 0.324
<200 copies/mL 11 (20.8) 36 (43.9) 0.006
PVL 4 mo post-ART
(log10 copies/mL)
2.15  1.08 1.71  0.82 0.014
>2 log10 copies/mL 21 (39.6) 13 (16.3) 0.002
<200 copies/mL 39 (73.6) 72 (90.0) 0.013
Data are presented as mean  SD or n (%).
ARTZ antiretroviral therapy; AZTZ zidovudine; HIVZ human
immunodeficiency virus; IDU Z injection drug user;
PVL Z plasma HIV-1 RNA load; SD Z standard deviation.
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higher prevalence of herpes zoster, ranging from 7.9% to
14.1%.8,9,19 The discrepancy may be attributable to the
different ethnicities and baseline CD4 counts of the patient
populations.8 Compared with a previous observational
study in Taiwan,7 this study showed lower incidence (6.5%
vs. 10.7%, p Z 0.006) with a significantly lower incidence
rate than that in the pre-cART era (3.61/100 person-years
vs. 17.2/100 person-years, p Z 0.004) but a similar inci-
dence rate when compared with that in the post-cART era
(3.61/100 person-years vs. 5.05/100 person-years,
p Z 0.754). The decline in the incidence of herpes zoster
was also demonstrated in other recent studies,8,10,19 which
could reflect the benefit of restoration of immunodefi-
ciency and viral suppression by cART.Please cite this article in press as: Lee Y-C, et al., Incidence and risk f
patients initiating combination antiretroviral therapy in Taiwan, Jou
dx.doi.org/10.1016/j.jmii.2016.04.011Our study found that baseline CD4 count < 200 cells/mL
and prior herpes zoster were independent risk factors for
the development of herpes zoster in patients initiating
cART. Several recent studies also demonstrated a clear
association between the CD4 counts and the risk of herpes
zoster.9,10,19,20 In the French study using insurance data-
bases, Grabar et al19 found an inverse doseeresponse
relationship between the CD4/CD8 ratio < 0.9 and the risk
of herpes zoster, independent of the CD4 count and PVL, in
multivariate analysis. An association between CD8 count
and the risk of herpes zoster has also been described by
other studies.21,22
In the caseecontrol study, we found that prior herpes
zoster and baseline PLV > 5 log10 copies/mL were risk
factors associated with development of herpes zoster,
which was different from those (prior herpes zoster and
baseline CD4 count < 200 cells/mL) identified in the overall
study population. Blank et al10 found that starting cART
within 90 days of the zoster episode, having a PVL >
400 copies/mL, and a CD4 < 350 cells/mL were associated
with increased risk of herpes zoster. These findings sug-
gested that markers of poor immune function, such as high
PVL and low CD4 count, were predisposing factors to the
development of herpes zoster, and early initiation of
appropriate regimens of cART may reduce the burden of
herpes zoster in HIV-positive patients.
Because of higher incidence and complications of herpes
zoster in HIV-positive patients, vaccination could provide
potential benefits. LAHZV is recommended to HIV-positive
adults with a CD4 count>200 cells/mL.15,16 Despite concerns
of causing disease in immunocompromised hosts, including
HIV-positive populations, by LAHZV,23,24 a recent study by
Shafran15 recommended the administration of LAHZV to HIV-
positive adults with a CD4 count >200 cells/mL, which was
safe and immunogenic with no cases of vaccine strain
infection. However, the lower CD4 counts, the higher the
probability of herpes zoster in HIV-positive patients. For HIV-
positive patients with CD4 counts < 200 cells/mL, a recom-
binant subunit vaccine might be an appropriate choice to
prevent herpes zoster.25 A recent phase 1/2a clinical trial by
Berkowitz et al18 noted that an adjuvanted herpes zoster
subunit candidate vaccine was immunogenic in both hu-
moral and cellular immunity and had a clinically acceptible
safety profile in HIV-positive adults, including patients with
cART and CD4 count < 200 cells/mL.
This study should be viewed with necessary caution in
light of several limitations. First, self-reported prior herpes
zoster was not documented by a health professional, but
high validity to self-reports of herpes zoster suggested that
herpes zoster misclassification was likely to be very low.26
Second, as patients might present with herpes zoster in a
local primary care facility, the incidence of herpes zoster
experienced by patients in this cohort was likely to be
underestimated. Third, information on complications of
herpes zoster were unavailable, such as postherpetic neu-
ralgia, disseminated herpes zoster, bacterial superinfec-
tion, ocular involvement, and meningoencephalitis. This
precludes us from evaluating the impact of herpes zoster on
HIV-positive patients. Fourth, our results were derived from
patients followed at a single, urban institution with a high
proportion of men who have sex with men, and the results
may not be generalized to other clinical settings.actors of herpes zoster in human immunodeficiency virus-positive
rnal of Microbiology, Immunology and Infection (2016), http://
Table 4 Multivariate analysis for risk factors associated with the development of zoster in matched pairs of HIV-positive
patients after initiation of combination antiretroviral therapy.
Variable Reference OR 95% CI p
Age Continuous variables 1.403 0.931e2.114 0.106
Prior zoster No prior zoster 4.735 1.122e19.990 0.034
Baseline PVL >5 log10 copies/mL Baseline PVL <5 log10 copies/mL 2.963 1.001e8.774 0.050
Baseline CD4 <200 cells/mL Baseline CD4 >200 cells/mL 1.191 0.389e3.645 0.760
CI Z confidence interval; HIV Z human immunodeficiency virus; OR Z odds ratio; PVL Z plasma HIV-1 RNA load.
6 Y.-C. Lee et al.
+ MODELIn conclusion, 6.5% of HIV-positive Taiwanese patients
developed herpes zoster after initiation of cART, with an
overall incidence rate of 3.61/100 patient-years. The
associated factors of zoster development included prior
herpes zoster and baseline CD4 count < 200 cells/mL or
baseline PVL > 5 log10 copies/mL.
Conflicts of interest
C.-C.H. has received research support from Janssen, Abb-
vie, and ViiV; and speaker honoraria from Bristol-Myers
Squibb, ViiV, Abbvie, and Gilead Sciences; and served on
advisory boards for Gilead Sciences and Abbvie. All other
authors declare no conflicts of interest.
Acknowledgments
We thank the patients for participating in this survey and
Taiwan Centers for Disease Control for the research grant
support. This study was supported by grants from Taiwan
Centers for Disease Control (MOHW103-CDC-C-114-000405
to C.-C. H.). The funding source played no role in study
design and conduct, data collection, analysis or interpre-
tation, writing of the manuscript, or the decision to submit
it for publication.
References
1. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O’Malley PM,
Underwood R, et al. Herpes zoster and human immunodefi-
ciency virus infection. J Infect Dis 1992;166:1153e6.
2. Gebo KA, Kalyani R, Moore RD, Polydefkis MJ. The incidence of,
risk factors for, and sequelae of herpes zoster among HIV pa-
tients in the highly active antiretroviral therapy era. J Acquir
Immune Defic Syndr 2005;40:169e74.
3. Engels EA, Rosenberg PS, Biggar RJ. Zoster incidence in human
immunodeficiency virus-infected hemophiliacs and homosexual
men, 1984e1997. J Infect Dis 1999;180:1784e9.
4. Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT,
Lange JM, et al. Herpes zoster, immunological deterioration
and disease progression in HIV-1 infection. AIDS 1995;9:
1153e8.
5. Friedman-Kien AE, La fleur FL, Gendler E, Hennessey NP,
Montagna R, Hallbert S, et al. Herpes zoster: a possible early
clinical sign for development of acquired immunodeficiency
syndrome in high-risk individuals. J Am Acad Dermatol 1986;
14:1023e8.
6. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes
zoster in adults infected with human immunodeficiency virus.
Clin Infect Dis 1995;21:370e5.Please cite this article in press as: Lee Y-C, et al., Incidence and risk f
patients initiating combination antiretroviral therapy in Taiwan, Jou
dx.doi.org/10.1016/j.jmii.2016.04.0117. Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH,
et al. Herpes zoster in HIV-1-infected patients in the era of
highly active antiretroviral therapy: a prospective observa-
tional study. Int J STD AIDS 2005;16:673e6.
8. Moanna A, Rimland D. Decreasing incidence of herpes zoster in
the highly active antiretroviral therapy era. Clin Infect Dis
2013;57:122e5.
9. Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S,
et al. Incidence and risk factors of herpes zoster among HIV-
positive patients in the German Competence Network for
HIV/AIDS (KompNet): a cohort study analysis. BMC Infect Dis
2013;13:372e80.
10. Blank LJ, Polydefkis MJ, Moore RD, Gebo KA. Herpes zos-
ter among persons living with HIV in the current antire-
troviral therapy era. J Acquir Immune Defic Syndr 2012;
61:203e7.
11. Pinchinat S, Cebria´n-Cuenca AM, Briout H, Johnson RW. Similar
herpes zoster incidence across Europe: results from a systemic
literature review. BMC Infect Dis 2013;13:170e9.
12. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of
herpes zoster. Arch Intern Med 1995;155:1605e9.
13. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS.
A population-based study of the incidence and complication
rates of herpes zoster before zoster vaccine introduction.
Mayo Clin Proc 2007;82:1341e9.
14. Vanhems P, Voisin L, Gayet-Ageron A, Trepo C, Cotte L,
Peyramond D, et al. The incidence of herpes zoster is less likely
than other opportunistic infections to be reduced by highly
active antiretroviral therapy. J Acquir Immune Defic Syndr
2005;38:111e3.
15. Shafran SD. Live attenuated herpes zoster vaccine for HIV-
infected adults. HIV Med 2015 Aug 27. http://dx.doi.or-
g/10.1111/hiv.12311 [Epub ahead of print].
16. Centers for Disease Control and Prevention, the National In-
stitutes of Health, and the HIV Medicine Association of the
Infectious Diseases Society of America. Guidelines for pre-
vention and treatment of opportunistic infections in HIV-
infected adults and adolescents. AIDSinfo website. Available
from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/
adult_oi.pdf. [accessed 10.01.16].
17. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J,
Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster sub-
unit vaccine in older adults. N Eng J Med 2015;372:2087e96.
18. Berkowitz EM, Moyle G, Stellbrink HJ, Schu¨rmann D, Kegg S,
Stoll M, et al. Safety and immunogenicity of an adjuvanted
herpes zoster subunit candidate vaccine in HIV-infected adults:
a phase 1/2a randomized, placebo-controlled study. J Infect
Dis 2015;211:1279e87.
19. Grabar S, Tattevin P, Selinger-Leneman H, de La
Blanchardiere A, de Truchis P, Rabaud C, et al. Incidence of
herpes zoster in HIV-infected adults in the combined ante-
ritroviral therapy era: results from the FHDH-ANRS CO4 cohort.
Clin Infect Dis 2015;60:1269e77.
20. Shearer K, Maskew M, Ajayi T, Berhanu R, Majuba P, Sanne I,
et al. Incidence and predictors of herpes zoster amongactors of herpes zoster in human immunodeficiency virus-positive
rnal of Microbiology, Immunology and Infection (2016), http://
Incidence and risk factors of herpes zoster 7
+ MODELantiretroviral therapy-naı¨ve patients initiating HIV treat-
ment in Johannesburg, South Africa. Int J Infect Dis 2014;23:
56e62.
21. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an
immune reconstitution disease after initiation of combination
antiretroviral therapy in patients with human immunodefi-
ciency virus type-1 infection. Am J Med 2001;110:605e9.
22. Martinez E, Gatell J, Moran Y, Aznar E, Buira E, Guelar A, et al.
High incidence of herpes zoster in patients with AIDS soon after
therapy with protease inhibitors. Clin Infect Dis 1998;27:
1510e3.Please cite this article in press as: Lee Y-C, et al., Incidence and risk f
patients initiating combination antiretroviral therapy in Taiwan, Jou
dx.doi.org/10.1016/j.jmii.2016.04.01123. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes
zoster: recommendations of the Advisory Committee on Im-
munization Practices (ACIP). MMWR Recomm Rep 2008;57:
1e30. quiz CE2e4.
24. Centers for Disease Control and Prevention. Update on herpes
zoster vaccine: licensure for persons aged 50 through 59 years.
MMWR Morb Mortal Wkly Rep 2011;60:1528.
25. Clark TG, Cassidy-Hanley D. Recombinant subunit vaccines:
potentials and constraints. Dev Biol (Basel) 2005;121:153e63.
26. Schmader K,George LK,NewtonR,Hamilton JD. The accuracy of
self-report of herpes zoster. J Clin Epidemiol 1994;47:1271e6.actors of herpes zoster in human immunodeficiency virus-positive
rnal of Microbiology, Immunology and Infection (2016), http://
